as 03-25-2025 3:33pm EST
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | ANDOVER |
Market Cap: | 2.3B | IPO Year: | 2019 |
Target Price: | $118.44 | AVG Volume (30 days): | 1.1M |
Analyst Decision: | Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 1.01 | EPS Growth: | N/A |
52 Week Low/High: | $55.00 - $177.37 | Next Earning Date: | 04-29-2025 |
Revenue: | $441,540,000 | Revenue Growth: | 82.74% |
Revenue Growth (this year): | 25.24% | Revenue Growth (next year): | 19.89% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Khayal Tamer I | TMDX | Chief Commercial Officer | Mar 3 '25 | Sell | $76.43 | 2,407 | $183,967.01 | 36,042 | |
Khayal Tamer I | TMDX | Chief Commercial Officer | Jan 7 '25 | Sell | $80.05 | 1,083 | $86,694.15 | 36,042 |
TMDX Breaking Stock News: Dive into TMDX Ticker-Specific Updates for Smart Investing
Motley Fool
4 days ago
Motley Fool
7 days ago
Insider Monkey
9 days ago
Motley Fool
15 days ago
Simply Wall St.
19 days ago
Argus Research
22 days ago
Simply Wall St.
22 days ago
Simply Wall St.
25 days ago
The information presented on this page, "TMDX TransMedics Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.